DOACs Reduce Dementia Risk Versus Warfarin in A-Fib
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Sept. 7, 2023 -- For patients with atrial fibrillation (AF), the use of direct-acting oral anticoagulants (DOACs) significantly reduces dementia risk compared with warfarin, according to a systematic review and meta-analysis published online Sept. 5 in the Journal of the American College of Cardiology: Asia.
Khi Yung Fong, from the National University of Singapore, and colleagues conducted a systematic review of studies reporting comparisons of dementia incidence between patients treated with DOACs and warfarin for AF. Data were included for 10 studies with 342,624 patients.
The researchers found that compared with warfarin, DOACs were associated with a significantly lower risk for developing dementia (hazard ratio, 0.88); the association was significant for Asian patients (hazard ratio, 0.81) but not non-Asian patients. In subgroup analyses, similar significance was seen for propensity score-matched studies and patients aged 65 to 75 years, but not for patients aged 75 years and older. A lower mean age corresponded to significantly greater favoring of DOACs over warfarin. In a network meta-analysis, significant reductions were seen in dementia risk for rivaroxaban, apixaban, and dabigatran versus warfarin (hazard ratios, 0.854, 0.881, and 0.871, respectively).
"The use of DOAC in AF significantly reduces dementia risk compared with warfarin, particularly in Asian patients. The possible reversal of this effect with increasing age merits further randomized trials with long-term follow-up," the authors write.
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
Gastroesophageal Reflux Disease Increases Risk for Atrial Fibrillation
TUESDAY, July 2, 2024 -- Gastroesophageal reflux disease (GERD) is associated with an increased incidence of atrial fibrillation, according to a study published online June 2...
Emergence of Psychosis in Alzheimer Disease Linked to Elevations in p-tau181
MONDAY, July 1, 2024 -- For individuals with Alzheimer disease (AD), the emergence of psychosis is associated with elevations in levels of plasma tau phosphorylated at threonine...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.